Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-008: Pembrolizumab + Lenvatinib vs Docetaxel in Advanced NSCLC
NCT03976375Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of lenvatinib, pembrolizumab, sponsored by Merck & Co.. Started Jun 2019; status: completed.
02
Drugs
lenvatinibpembrolizumab
Beyond the preview
Go deeper on NCT03976375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976375.